- Home
- VCYT vs LIVN Comparison
VCYT vs LIVN Comparison
Compare VCYT & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCYT
- LIVN
- Stock Information
- Founded
- VCYT 2006
- LIVN 1987
- Country
- VCYT United States
- LIVN United Kingdom
- Employees
- VCYT N/A
- LIVN N/A
- Industry
- VCYT Medical Specialities
- LIVN Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- VCYT Health Care
- LIVN Health Care
- Exchange
- VCYT Nasdaq
- LIVN Nasdaq
- Market Cap
- VCYT 2.4B
- LIVN 2.1B
- IPO Year
- VCYT 2013
- LIVN 1993
- Fundamental
- Price
- VCYT $31.83
- LIVN $54.53
- Analyst Decision
- VCYT Buy
- LIVN Strong Buy
- Analyst Count
- VCYT 9
- LIVN 7
- Target Price
- VCYT $39.89
- LIVN $59.71
- AVG Volume (30 Days)
- VCYT 921.3K
- LIVN 583.7K
- Earning Date
- VCYT 11-05-2025
- LIVN 10-29-2025
- Dividend Yield
- VCYT N/A
- LIVN N/A
- EPS Growth
- VCYT N/A
- LIVN N/A
- EPS
- VCYT 0.34
- LIVN N/A
- Revenue
- VCYT $479,129,000.00
- LIVN $1,309,329,000.00
- Revenue This Year
- VCYT $14.19
- LIVN $11.29
- Revenue Next Year
- VCYT $9.68
- LIVN $6.59
- P/E Ratio
- VCYT $95.21
- LIVN N/A
- Revenue Growth
- VCYT 19.91
- LIVN 8.23
- 52 Week Low
- VCYT $22.61
- LIVN $32.48
- 52 Week High
- VCYT $47.32
- LIVN $58.91
- Technical
- Relative Strength Index (RSI)
- VCYT 58.59
- LIVN 50.60
- Support Level
- VCYT $30.67
- LIVN $56.42
- Resistance Level
- VCYT $32.34
- LIVN $57.53
- Average True Range (ATR)
- VCYT 1.18
- LIVN 1.35
- MACD
- VCYT -0.06
- LIVN -0.70
- Stochastic Oscillator
- VCYT 73.71
- LIVN 10.25
About VCYT Veracyte Inc.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
About LIVN LivaNova PLC
UK-based Livanova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, Livanova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.